Questions for David & The Board...
David, as a fellow PARSian, I certainly share your enthusiasm about the NATURE article... and feel that I must defer to you in these matters because of your long-term familiarity with PARS.
However, I do have a couple of questions:
(1): To anyone's knowledge, does the research cited in NATURE utilize a cannabinoid that "belongs" to PARS? From an abstract that I read, it seemed that this was NOT the case. But, given the density of the writing, I may have missed something important.
(2): In order for Wall Street to make the "synaptic" connection between the NATURE article and PARS' own preliminary research, won't PARS have to issue some kind Press Release? Or will potential investors and analysts just put two and two together on their own? As I recall, last year there was an announcement about (I believe) NIH's interest in marijuana-related research. At the time, several posters hoped that PARS would issue a statement that, in essence, "coat-tailed" on the surge of publicity... but, nothing happened.
Now, that said, I certainly could be missing something. Truth to tell, my knowledge of science would barely fill a thimble. And, it doesn't take a scientist to see that PARS and biotechs in general are on quite a roll. Maybe this NATURE article is just the "jazz" we need to push the price into the stratosphere.
My Best Regards,
c m/Ormand33 |
